Works matching IS 03407004 AND DT 2022 AND VI 71 AND IP 2

Results: 21

Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 473, doi. 10.1007/s00262-021-03010-6

By:

Narla, Rama Krishna;
Modi, Hardik;
Bauer, Daniel;
Abbasian, Mahan;
Leisten, Jim;
Piccotti, Joseph R.;
Kopytek, Stephan;
Eckelman, Brendan P.;
Deveraux, Quinn;
Timmer, John;
Zhu, Dan;
Wong, Lilly;
Escoubet, Laure;
Raymon, Heather K.;
Hariharan, Kandasamy

Publication type:

Article

Correction to: OSCC cell‑secreted exosomal CMTM6 induced M2‑like macrophages polarization via ERK1/2 signaling pathway.

Published in:

2022

By:

Pang, Xin;
Wang, Sha‑sha;
Zhang, Mei;
Jiang, Jian;
Fan, Hua‑yang;
Wu, Jia‑shun;
Wang, Hao‑fan;
Liang, Xin‑hua;
Tang, Ya‑ling

Publication type:

Correction Notice

Identification of KRAS G12V associated clonal neoantigens and immune microenvironment in long-term survival of pancreatic adenocarcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 491, doi. 10.1007/s00262-021-03012-4

By:

Wang, Chao;
Shi, Min;
Zhang, Lei;
Ji, Jun;
Xie, Ruyan;
Wu, Chao;
Guo, Xianchao;
Yang, Ying;
Zhou, Wei;
Peng, Chenhong;
Zhang, Henghui;
Yuan, Fei;
Zhang, Jun

Publication type:

Article

Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 461, doi. 10.1007/s00262-021-03000-8

By:

Kobayashi, Takashi;
Ito, Katsuhiro;
Kojima, Takahiro;
Maruyama, Satoru;
Mukai, Shoichiro;
Tsutsumi, Masakazu;
Miki, Jun;
Okuno, Tomoya;
Yoshio, Yuko;
Matsumoto, Hiroaki;
Shimazui, Toru;
Segawa, Takehiko;
Karashima, Takashi;
Masui, Kimihiko;
Fukuta, Fumimasa;
Tashiro, Kojiro;
Imai, Kazuto;
Suekane, Shigetaka;
Nagasawa, Seiji;
Higashi, Shin

Publication type:

Article

Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 445, doi. 10.1007/s00262-021-02998-1

By:

Kursunel, M. Alper;
Taskiran, Ekim Z.;
Tavukcuoglu, Ece;
Yanik, Hamdullah;
Demirag, Funda;
Karaosmanoglu, Beren;
Ozbay, Feyza Gul;
Uner, Aysegul;
Esendagli, Dorina;
Kizilgoz, Derya;
Yilmaz, Ulku;
Esendagli, Gunes

Publication type:

Article

Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 387, doi. 10.1007/s00262-021-02997-2

By:

Jo, Hitomi;
Yoshida, Tatsuya;
Horinouchi, Hidehito;
Yagishita, Shigehiro;
Matsumoto, Yuji;
Shinno, Yuki;
Okuma, Yusuke;
Goto, Yasushi;
Yamamoto, Noboru;
Takahashi, Kazuhisa;
Motoi, Noriko;
Ohe, Yuichiro

Publication type:

Article

SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 399, doi. 10.1007/s00262-021-02995-4

By:

Yuan, Lu;
Wu, Xixi;
Zhang, Longshan;
Yang, Mi;
Wang, Xiaoqing;
Huang, Wenqi;
Pan, Hua;
Wu, Yuting;
Huang, Jihong;
Liang, Wenyu;
Li, Jiaxin;
Zhu, Xiaodi;
Wang, Shuang;
Guan, Jian;
Liu, Laiyu

Publication type:

Article

Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 365, doi. 10.1007/s00262-021-02994-5

By:

Takeuchi, Eiji;
Okano, Yoshio;
Machida, Hisanori;
Atagi, Katsuhiro;
Kondou, Yoshihiro;
Kadota, Naoki;
Hatakeyama, Nobuo;
Naruse, Keishi;
Shinohara, Tsutomu

Publication type:

Article

Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 373, doi. 10.1007/s00262-021-02990-9

By:

Lazarus, Gilbert;
Budiman, Refael Alfa;
Rinaldi, Ikhwan

Publication type:

Article

T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 339, doi. 10.1007/s00262-021-02992-7

By:

Harada, Mamoru;
Iida, Yuichi;
Kotani, Hitoshi;
Minami, Takafumi;
Komohara, Yoshihiro;
Eto, Masatoshi;
Yoshikawa, Kazuhiro;
Uemura, Hirotsugu

Publication type:

Article

Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vγ9Vδ2 T cells by targeting specificity protein 1.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 311, doi. 10.1007/s00262-021-02991-8

By:

Li, Juntao;
Sun, Linqing;
Chen, Yanjun;
Zhu, Jinghan;
Shen, Jin;
Wang, Jiayu;
Gu, Yanzheng;
Zhang, Guangbo;
Wang, Mingyuan;
Shi, Tongguo;
Chen, Weichang

Publication type:

Article

Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 277, doi. 10.1007/s00262-021-02978-5

By:

Liu, Guanfang;
Zhang, Qi;
Yang, Jingying;
Li, Xiaomin;
Xian, Luhua;
Li, Wenmin;
Lin, Ting;
Cheng, Juan;
Lin, Qiwen;
Xu, Xiuzhang;
Li, Qin;
Lin, Yu;
Zhou, Maohua;
Shen, Erxia

Publication type:

Article

T cells, particularly activated CD4<sup>+</sup> cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 237, doi. 10.1007/s00262-021-02976-7

By:

Wang, Zhaoming;
Chimenti, Michael S.;
Strouse, Christopher;
Weiner, George J.

Publication type:

Article

Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 433, doi. 10.1007/s00262-021-02993-6

By:

Holmberg-Thydén, Staffan;
Dufva, Inge Høgh;
Gang, Anne Ortved;
Breinholt, Marie Fredslund;
Schejbel, Lone;
Andersen, Mette Klarskov;
Kadivar, Mohammad;
Svane, Inge Marie;
Grønbæk, Kirsten;
Hadrup, Sine Reker;
El Fassi, Daniel

Publication type:

Article

Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 327, doi. 10.1007/s00262-021-02985-6

By:

Fountzilas, Elena;
Lampaki, Sofia;
Koliou, Georgia-Angeliki;
Koumarianou, Anna;
Levva, Sofia;
Vagionas, Anastasios;
Christopoulou, Athina;
Laloysis, Athanasios;
Psyrri, Amanda;
Binas, Ioannis;
Mountzios, Giannis;
Kentepozidis, Nikolaos;
Kotsakis, Athanassios;
Saloustros, Emmanouil;
Boutis, Anastasios;
Nikolaidi, Adamantia;
Fountzilas, George;
Georgoulias, Vassilis;
Chrysanthidis, Miltiadis;
Kotteas, Elias

Publication type:

Article

Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 289, doi. 10.1007/s00262-021-02984-7

By:

Marijt, Koen A.;
Griffioen, Lisa;
Blijleven, Laura;
van der Burg, Sjoerd. H.;
van Hall, Thorbald

Publication type:

Article

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 251, doi. 10.1007/s00262-021-02981-w

By:

Budczies, Jan;
Kirchner, Martina;
Kluck, Klaus;
Kazdal, Daniel;
Glade, Julia;
Allgäuer, Michael;
Kriegsmann, Mark;
Heußel, Claus-Peter;
Herth, Felix J.;
Winter, Hauke;
Meister, Michael;
Muley, Thomas;
Goldmann, Torsten;
Fröhling, Stefan;
Wermke, Martin;
Waller, Cornelius F.;
Tufman, Amanda;
Reck, Martin;
Peters, Solange;
Schirmacher, Peter

Publication type:

Article

Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 353, doi. 10.1007/s00262-021-02989-2

By:

Ni, Haiqing;
Cao, Lei;
Wu, Zhihai;
Wang, Li;
Zhou, Shuaixiang;
Guo, Xiaoli;
Gao, Yarong;
Jing, Hua;
Wu, Min;
Liu, Yang;
Ding, Jiazheng;
Zhang, Pan;
Zhou, Ying;
Chen, Bingliang;
Xiong, Yao;
Sun, Jiya;
Prinz, Bianka;
Baruah, Hemanta;
Geoghegan, James;
Yu, Michael

Publication type:

Article

Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 301, doi. 10.1007/s00262-021-02987-4

By:

Ye, Ruiting;
Zeng, Han;
Liu, Zhaopei;
Jin, Kaifeng;
Liu, Chunnan;
Yan, Sen;
Yu, Yanze;
You, Runze;
Zhang, Hongyi;
Chang, Yuan;
Wang, Yiwei;
Liu, Li;
Zhu, Yu;
Xu, Jiejie;
Xu, Le;
Wang, Zewei

Publication type:

Article

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 417, doi. 10.1007/s00262-021-02973-w

By:

Italiano, Antoine;
Cassier, Philippe A.;
Lin, Chia-Chi;
Alanko, Tuomo;
Peltola, Katriina J.;
Gazzah, Anas;
Shiah, Her-Shyong;
Calvo, Emiliano;
Cervantes, Andrés;
Roda, Desamparados;
Tosi, Diego;
Gao, Bo;
Millward, Michael;
Warburton, Lydia;
Tanner, Minna;
Englert, Stefan;
Lambert, Stacie;
Parikh, Apurvasena;
Afar, Daniel E.;
Vosganian, Gregory

Publication type:

Article

Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 2, p. 267, doi. 10.1007/s00262-021-02964-x

By:

Wang, Yang;
Nie, Jun;
Dai, Ling;
Hu, Weiheng;
Zhang, Jie;
Chen, Xiaoling;
Ma, Xiangjuan;
Tian, Guangming;
Han, Jindi;
Han, Sen;
Wu, Di;
Long, Jieran;
Zhang, Ziran;
Fang, Jian

Publication type:

Article